ACC Ltd
ACCACC Ltd is cheap for a reason. The P/E sits at the 9th percentile of its own range, and the quarters are still getting worse.
The sharpest disagreement: the P/E sits at the 9th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn.
The price is in a downtrend (93 weeks in) while the P/E sits at the 9th percentile of its own 10-year range. Underneath, the last four quarters read deteriorating — profit −60.8% year on year, and 49% of the last 3 years' profit arrived as cash. What settles it: whether the quarters turn before the discount closes.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
ACC Ltd trades at ₹1,357, in a downtrend and 93 weeks into that stage. That is −11.5% against its own 200-day average. It sits at 8% of a 52-week range of ₹1,314 to ₹1,886. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (42 weeks and counting).
Today the stock is in a downtrend — week 93 of stage 4, confirmed. At ₹1,357 it trades −11.5% versus its 200-day average and sits at 8% of its 52-week range (₹1,314–₹1,886).
Against the market, two honest reads. Cumulative: over the last 10.4 years the stock moved +11% while the NIFTY 500 moved +276% — behind the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (42 weeks and counting; last ahead the week of 2025-10-31) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
ACC Ltd trades at 13.4× P/E, near the bottom of its own range — cheaper only 9% of the time. Its long-run median P/E is 23.4×, measured across 10.4 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 13.4× is near the bottom of its own range — cheaper only 9% of the time, against a long-run median of 23.4× measured over 10.4 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved −11.0% against a −24.4% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the −10.7%/yr price move, ~−1.9%/yr came from earnings growth and ~−8.8 pp from the multiple (compressing); over 10y, of the −2.2%/yr price move, ~+10.6%/yr came from earnings growth and ~−12.8 pp from the multiple (compressing). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
ACC Ltd reads as deteriorating on its fundamental arc. Deteriorating — profit and EPS growth are shrinking (profit growth −21.1% latest against +377.5% at its 12-quarter best), ROCE slipping at 10.9%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +19.3% | +5.3% | +10.0% | +9.0% |
| Profit | −11.0% | +34.2% | +2.8% | +12.5% |
| EPS | −11.0% | +34.2% | +2.8% | +12.5% |
| Share price | −24.4% | −11.4% | −10.7% | −2.2% |
4-Factor Sector Score
42.5/100 — rank 18 of 26 in Cement · 94% evidence confidence
ACC Ltd scores 42.5 out of 100 against the 26 companies it is compared with in Cement, ranking 18. Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
The four contributions add to the total exactly: 9.1 + 9.9 + 16.7 + 6.8 = 42.5. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
ACC Ltd reported ₹5,808 Cr of revenue in the Jun 26 quarter, −4.6% year on year. Over 11 years it has compounded at 7.5% a year. The last full year, Mar 26, came in at ₹25,962 Cr. The last four reported quarters add to ₹25,442 Cr.
Mar 26 revenue came in at ₹25,962 Cr (+19.3% on the year), capping 11 years at 7.5% compound. The latest quarter (Jun 26) printed ₹5,808 Cr, −4.6% year on year.
Pace check: the last four quarters averaged +12.6% growth against the decade's 7.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +11.5% over the last 4 quarters against +12.9%/yr over the last 8 — stabilising; TTM profit −21.1% vs −7.5%/yr — rolling over.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
ACC Ltd's operating margin is 8.0% in the Jun 26 quarter, −5.0 percentage points against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0% to 19.0%. The current quarter is running below every full year in that window.
The latest quarter's operating margin is 8.0%, −5.0 pp against the same quarter a year ago. Across 13 fiscal years the operating margin has ranged 9.0%–19.0%.
🚨 Why the margin moved: operating margin went −4.9 pp year on year while gross margin went −5.7 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
ACC Ltd earned ₹147 Cr of net profit in the Jun 26 quarter, −60.8% year on year. Full-year Mar 26 profit was ₹2,137 Cr. The 11-year compound rate is 12.5%. That is 2.5% of the quarter's revenue. The same quarter a year earlier earned ₹375 Cr.
Jun 26 profit was ₹147 Cr, −60.8% year on year. On the full year, Mar 26 printed ₹2,137 Cr (−11.0%), and the 11-year compound rate is 12.5%.
🚨 Why profit moved: revenue contributed −4.6% and the margin −5.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +66.8% vs revenue +12.6%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 49% of ACC Ltd's reported profit arrived as operating cash — a gap worth watching. In Mar 26 that was ₹−1,364 Cr of operating cash against ₹2,137 Cr of profit. After ₹1,711 Cr of capital spending, ₹−3,075 Cr was left as free cash.
Mar 26: operating cash of ₹−1,364 Cr against reported profit of ₹2,137 Cr, leaving free cash of ₹−3,075 Cr after ₹1,711 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 49% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why conversion sits at 49%: the cash cycle stretched 96 days between FY20 and Mar 26 — more of each rupee of profit waits inside the cycle before arriving. Less than 70% of profit arriving as cash is the thing to watch on this page.
Router verdict: conversion is below par and the cash cycle has stretched 96 days — the next section's job is to find where the cash is stuck.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
ACC Ltd's cash conversion cycle runs 32 days in Mar 26, up from −64 days in FY20. Capital spending ran ₹7,291 Cr over the last 3 years. At Mar 26 sales of ₹25,962 Cr each day of that cycle holds about ₹71.1 Cr, so roughly ₹2,276 Cr sits inside the business at any moment.
Mar 26: debtors at 54 days, inventory at 58 days — roughly 1.9 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 32 days, looser than FY20's −64.
The full loop: cash goes out to suppliers and production on day 0; stock waits 58 days to sell; customers pay about 54 days after that; and suppliers themselves are paid at 80 days — netting out to the 32-day cycle.
In money terms: at Mar 26 sales of ₹25,962 Cr, each day of the cycle holds about ₹71.1 Cr — so the 32-day loop keeps roughly ₹2,276 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹7,291 Cr over the last 3 fiscal years against ₹3,004 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹2,227 Cr (Mar 26) — capacity paid for but not yet earning.
The synthesis: the working-capital loop is the cash sink the router flagged — watch the cycle, not the P&L.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
ACC Ltd earns a ROCE of 11% in Mar 26. That is up from a trough of 9% in Mar 23. Return on invested capital clears the cost of that capital by −4.7 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 8.2% net margin on 0.94× asset turns.
Mar 26 ROCE is 11%, recovered from a Mar 23 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (Mar 26): 8.2% net margin × 0.94× asset turns × 1.34× balance-sheet leverage ≈ 10.3% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 7.3% − 12.0% = a −4.7 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
ACC Ltd carries total debt of ₹429 Cr against shareholder equity of ₹20,554 Cr as of Mar 26, a debt-to-equity of 0.02 — effectively unlevered. On the annual view that ratio went from 0.01 in FY23 to 0.02 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹429 Cr against shareholder equity of ₹20,554 Cr — a debt-to-equity of 0.02. On the annual view, debt-to-equity went from 0.01 (FY23) to 0.02 (FY26). The returns on this page are earned, not borrowed.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 3.7 points of ACC Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 21.1% of the company. Foreign institutions moved +0.2 points over the same window, to 5.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −3.7 points over 8 quarters to 21.1%; Foreign institutions: +0.2 points over 8 quarters to 5.8%; Promoters: +0.0 points over 8 quarters to 56.7%.
🚨 Why the register moved: domestic institutions drove it (−3.7 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
ACC Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Star Cement LtdSTARCEMENT | 76.0/100Favorable setup90% evidence | ASLEEP | 29.9/35 Revenue 19.4% · PAT 100% · OPM change 2 pp 88% evidence | 22.4/25 ROCE 16.7% · OPM 27% 100% evidence | 11.3/20 P/E 20.4× · PEG 1.11 100% evidence | 12.4/20 RS sector 13.8% · RS bench -13.2% · 1Y -12.5%1 of 10 weeks ahead 70% evidence |
| Exact sum: 29.9 + 22.4 + 11.3 + 12.4 = 76 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2NCL Industries LtdNCLIND | 69.7/100Favorable setup83% evidence | FADING | 25.3/35 Revenue 1.8% · PAT 100% · OPM change 7 pp 83% evidence | 18.0/25 ROCE 14.5% · OPM 13% 95% evidence | 15.0/20 P/E 6.3× · PEG — 50% evidence | 11.4/20 RS sector 2.1% · RS bench -6.3% · 1Y -18.8%2 of 12 weeks ahead 100% evidence |
| Exact sum: 25.3 + 18 + 15 + 11.4 = 69.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 3UltraTech Cement LtdULTRACEMCO | 63.1/100Mixed-positive evidence76% evidence | TURNING | 21.9/35 Revenue 17.2% · PAT 26.7% · OPM change -1 pp 95% evidence | 17.1/25 ROCE 12.7% · OPM 20% 76% evidence | 9.2/20 P/E 40.7× · PEG — 50% evidence | 14.9/20 RS sector 17% · RS bench -1.4% · 1Y -2.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.9 + 17.1 + 9.2 + 14.9 = 63.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Mangalam Cement LtdMANGLMCEM | 62.9/100Mixed-positive evidence96% evidence | FADING | 21.6/35 Revenue 4.6% · PAT 100% · OPM change 0 pp 88% evidence | 11.7/25 ROCE 11% · OPM 11% 100% evidence | 16.0/20 P/E 17.5× · PEG 0.6 100% evidence | 13.6/20 RS sector 24.1% · RS bench 14.9% · 1Y 31.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 11.7 + 16 + 13.6 = 62.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rain Industries LtdRAIN | 62.5/100Mixed-positive evidence64% evidence | BREAKING OUT | 22.9/35 Revenue 14.4% · PAT 100% · OPM change 5 pp 62% evidence | 9.4/25 ROCE 8.3% · OPM 15% 76% evidence | 10.2/20 P/E 24.9× · PEG — 15% evidence | 20.0/20 RS sector 61.8% · RS bench 49.7% · 1Y 43.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 22.9 + 9.4 + 10.2 + 20 = 62.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Orient Cement LtdORIENTCEM | 58.2/100Mixed-positive evidence93% evidence | ASLEEP | 17.6/35 Revenue -12.1% · PAT -19.3% · OPM change 3 pp 100% evidence | 16.9/25 ROCE 16.5% · OPM 24% 100% evidence | 16.1/20 P/E 13.2× · PEG 0.25 65% evidence | 7.6/20 RS sector -12% · RS bench -20.1% · 1Y -45.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 16.9 + 16.1 + 7.6 = 58.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Dalmia Bharat LtdDALBHARAT | 53.4/100Mixed-positive evidence94% evidence | ASLEEP | 13.0/35 Revenue 7.6% · PAT 0.4% · OPM change -3 pp 100% evidence | 12.8/25 ROCE 7.6% · OPM 21% 100% evidence | 15.3/20 P/E 30.7× · PEG 0.72 100% evidence | 12.3/20 RS sector 12.6% · RS bench -11.9% · 1Y -19.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 12.8 + 15.3 + 12.3 = 53.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 8Shree Cement LtdSHREECEM | 51.8/100Mixed-positive evidence97% evidence | BREAKING OUT | 15.0/35 Revenue 12.6% · PAT 9.9% · OPM change -5 pp 95% evidence | 13.0/25 ROCE 10.3% · OPM 20% 95% evidence | 9.2/20 P/E 57.7× · PEG 0.96 100% evidence | 14.6/20 RS sector 5.1% · RS bench -3.7% · 1Y -15.8%3 of 12 weeks ahead 100% evidence |
| Exact sum: 15 + 13 + 9.2 + 14.6 = 51.8 · Decision use: Price leads the evidence: RS versus the benchmark is -3.7%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9JSW Cement LtdJSWCEMENT | 50.8/100Thin evidence · provisional51% evidence | TURNING | 18.6/35 Revenue 12% · PAT -80% · OPM change 5 pp 83% evidence | 12.1/25 ROCE 11.1% · OPM 19% 76% evidence | 10.1/20 P/E 27.8× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y -8.9%5 of 10 weeks ahead 0% evidence |
| Exact sum: 18.6 + 12.1 + 10.1 + 10 = 50.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10K C P LtdKCP | 49.4/100Mixed-negative evidence77% evidence | ASLEEP | 13.5/35 Revenue 1.9% · PAT 8.7% · OPM change 1 pp 83% evidence | 16.1/25 ROCE 12.2% · OPM 17% 95% evidence | 13.9/20 P/E 10.3× · PEG — 50% evidence | 5.9/20 RS sector -14% · RS bench -9.4% · 1Y -23.5%3 of 11 weeks ahead 70% evidence |
| Exact sum: 13.5 + 16.1 + 13.9 + 5.9 = 49.4 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11HeidelbergCement India LtdHEIDELBERG | 48.6/100Mixed-negative evidence100% evidence | ASLEEP | 14.5/35 Revenue 6.6% · PAT 2.6% · OPM change -4 pp 100% evidence | 14.7/25 ROCE 14.7% · OPM 11% 100% evidence | 13.7/20 P/E 28.5× · PEG 0.82 100% evidence | 5.7/20 RS sector -5.1% · RS bench -13.3% · 1Y -28.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 14.7 + 13.7 + 5.7 = 48.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 12J K Cements LtdJKCEMENT | 48.1/100Mixed-negative evidence94% evidence | TURNING | 11.2/35 Revenue 15.9% · PAT -7.1% · OPM change -5 pp 100% evidence | 16.4/25 ROCE 15.1% · OPM 16% 100% evidence | 8.1/20 P/E 43.1× · PEG 1.46 100% evidence | 12.4/20 RS sector 10.4% · RS bench -7.1% · 1Y -16%0 of 10 weeks ahead 70% evidence |
| Exact sum: 11.2 + 16.4 + 8.1 + 12.4 = 48.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13The Ramco Cements LtdRAMCOCEM | 47.3/100Mixed-negative evidence90% evidence | ASLEEP | 20.6/35 Revenue 6% · PAT 100% · OPM change 1 pp 88% evidence | 13.2/25 ROCE 6.1% · OPM 14% 100% evidence | 1.2/20 P/E 732× · PEG 4.14 100% evidence | 12.3/20 RS sector 11.1% · RS bench -10.1% · 1Y -19.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 20.6 + 13.2 + 1.2 + 12.3 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14JK Lakshmi Cement LtdJKLAKSHMI | 47.3/100Mixed-negative evidence65% evidence | ASLEEP | 17.4/35 Revenue 9.2% · PAT 49.6% · OPM change -5 pp 83% evidence | 13.9/25 ROCE 12% · OPM 14% 76% evidence | 10.6/20 P/E 17.6× · PEG — 15% evidence | 5.4/20 RS sector -8.2% · RS bench -23.6% · 1Y -40.3%0 of 10 weeks ahead 70% evidence |
| Exact sum: 17.4 + 13.9 + 10.6 + 5.4 = 47.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Nuvoco Vistas Corporation LtdNUVOCO | 47.1/100Mixed-negative evidence87% evidence | TURNING | 21.0/35 Revenue 9.5% · PAT 100% · OPM change 0 pp 100% evidence | 9.6/25 ROCE 7.1% · OPM 18% 100% evidence | 4.8/20 P/E 29.7× · PEG 8.14 65% evidence | 11.7/20 RS sector 3.6% · RS bench -5% · 1Y -16.5%4 of 10 weeks ahead 70% evidence |
| Exact sum: 21 + 9.6 + 4.8 + 11.7 = 47.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16India Cements LtdINDIACEM | 45.4/100Mixed-negative evidence75% evidence | ASLEEP | 21.3/35 Revenue 7% · PAT 100% · OPM change 7 pp 74% evidence | 3.8/25 ROCE 1.2% · OPM 15% 100% evidence | 5.4/20 P/E 91.4× · PEG — 50% evidence | 14.9/20 RS sector 20% · RS bench -2% · 1Y 10.8%0 of 10 weeks ahead 70% evidence |
| Exact sum: 21.3 + 3.8 + 5.4 + 14.9 = 45.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Deccan Cements LtdDECCANCE | 43.7/100Mixed-negative evidence70% evidence | ASLEEP | 22.6/35 Revenue 20.6% · PAT 100% · OPM change -3 pp 83% evidence | 7.9/25 ROCE 3.3% · OPM 8.1% 95% evidence | 9.1/20 P/E 43.4× · PEG — 15% evidence | 4.1/20 RS sector -12.9% · RS bench -29.1% · 1Y -47.7%0 of 10 weeks ahead 70% evidence |
| Exact sum: 22.6 + 7.9 + 9.1 + 4.1 = 43.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18ACC Ltdthis pageACC | 42.5/100Mixed-negative evidence94% evidence | ASLEEP | 9.1/35 Revenue 11.6% · PAT -21.1% · OPM change -5 pp 100% evidence | 9.9/25 ROCE 11.2% · OPM 8% 100% evidence | 16.7/20 P/E 13.4× · PEG 0.92 100% evidence | 6.8/20 RS sector -6.7% · RS bench -16.8% · 1Y -26.5%0 of 10 weeks ahead 70% evidence |
| Exact sum: 9.1 + 9.9 + 16.7 + 6.8 = 42.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Birla Corporation LtdBIRLACORPN | 41.0/100Mixed-negative evidence94% evidence | ASLEEP | 17.4/35 Revenue 3.9% · PAT 44.6% · OPM change -1 pp 100% evidence | 10.4/25 ROCE 9.8% · OPM 13% 100% evidence | 8.8/20 P/E 12.3× · PEG 3.92 100% evidence | 4.4/20 RS sector -14% · RS bench -17.4% · 1Y -37.4%3 of 9 weeks ahead 70% evidence |
| Exact sum: 17.4 + 10.4 + 8.8 + 4.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20Sagar Cements LtdSAGCEM | 41.0/100Mixed-negative evidence66% evidence | ASLEEP | 19.5/35 Revenue 13.4% · PAT 79.7% · OPM change -8 pp 95% evidence | 5.1/25 ROCE 2% · OPM 10% 76% evidence | 10.0/20 P/E — · PEG — 0% evidence | 6.4/20 RS sector -8.1% · RS bench -16.3% · 1Y -28.1%0 of 10 weeks ahead 70% evidence |
| Exact sum: 19.5 + 5.1 + 10 + 6.4 = 41 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Ambuja Cements LtdAMBUJACEM | 38.9/100Mixed-negative evidence82% evidence | ASLEEP | 9.4/35 Revenue 7.1% · PAT -5.9% · OPM change -2 pp 95% evidence | 11.0/25 ROCE 5.6% · OPM 17% 76% evidence | 12.6/20 P/E 22.8× · PEG — 50% evidence | 5.9/20 RS sector -7.2% · RS bench -15.1% · 1Y -29.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.4 + 11 + 12.6 + 5.9 = 38.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Saurashtra Cement LtdSAURASHCEM | 38.8/100Mixed-negative evidence76% evidence | ASLEEP | 19.7/35 Revenue 8.4% · PAT 87.5% · OPM change -5 pp 83% evidence | 4.8/25 ROCE 2.5% · OPM 6% 95% evidence | 9.5/20 P/E 30.9× · PEG — 15% evidence | 4.8/20 RS sector -16.6% · RS bench -24.6% · 1Y -41.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.7 + 4.8 + 9.5 + 4.8 = 38.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Prism Johnson LtdPRSMJOHNSN | 38.2/100Mixed-negative evidence69% evidence | ASLEEP | 12.1/35 Revenue 6.3% · PAT -33.3% · OPM change -2 pp 83% evidence | 5.9/25 ROCE 5.9% · OPM 8% 76% evidence | 8.6/20 P/E — · PEG — 35% evidence | 11.6/20 RS sector 14.3% · RS bench -20.9% · 1Y -32.2%1 of 10 weeks ahead 70% evidence |
| Exact sum: 12.1 + 5.9 + 8.6 + 11.6 = 38.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24BIGBLOC Construction LtdBIGBLOC | 36.7/100Thin evidence · provisional59% evidence | ASLEEP | 15.4/35 Revenue 26.2% · PAT -80% · OPM change -1.6 pp 62% evidence | 5.8/25 ROCE 1.8% · OPM 7.3% 95% evidence | 10.0/20 P/E — · PEG — 0% evidence | 5.5/20 RS sector -9.7% · RS bench -17.9% · 1Y -24.7%3 of 10 weeks ahead 70% evidence |
| Exact sum: 15.4 + 5.8 + 10 + 5.5 = 36.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Shree Digvijay Cement Co. LtdSHREDIGCEM | 31.2/100Adverse evidence81% evidence | ASLEEP | 10.8/35 Revenue 19.6% · PAT -35% · OPM change -3.5 pp 95% evidence | 8.2/25 ROCE 6.4% · OPM 8.7% 95% evidence | 6.1/20 P/E 59.4× · PEG — 50% evidence | 6.1/20 RS sector -12.4% · RS bench -10.9% · 1Y -15.8%4 of 10 weeks ahead 70% evidence |
| Exact sum: 10.8 + 8.2 + 6.1 + 6.1 = 31.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 26Shiva Cement LtdSHIVACEM | 36.5/100Thin evidence · provisional42% evidence | 18.1/35 Revenue 19.7% · PAT -47.1% · OPM change 15 pp 40% evidence | 5.4/25 ROCE -3% · OPM 1% 57% evidence | 10.0/20 P/E — · PEG — 0% evidence | 3.0/20 RS sector -27.5% · RS bench -36.4% · 1Y -54.1%0 of 12 weeks ahead to 2026-03-08 70% evidence | |
| Exact sum: 18.1 + 5.4 + 10 + 3 = 36.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is ACC Ltd's share price today?
ACC Ltd trades at ₹1,357, −24.4% over the past year. The company is valued at ₹25,490 Cr. The stock sits at 8% of its 52-week range of ₹1,314–₹1,886, −11.5% versus its 200-day average. On the tape, the price is in a downtrend, 93 weeks in. — as of 31 July 2026.
What were ACC Ltd's latest quarterly results?
ACC Ltd reported revenue of ₹5,808 Cr and net profit of ₹147 Cr for the Jun 26 quarter. Revenue fell 4.6% and profit fell 60.8% year on year. Earnings per share were ₹7.83. The operating margin was 8.0%, 5.0 pp lower than a year earlier. — as of 31 July 2026.
What is ACC Ltd's revenue?
ACC Ltd reported revenue of ₹5,808 Cr in the Jun 26 quarter, −4.6% year on year. For the full Mar 26 fiscal year, revenue was ₹25,962 Cr (+19.3%). Over the last 11 years revenue compounded at 7.5% a year. — as of 31 July 2026.
What is ACC Ltd's profit?
ACC Ltd earned ₹147 Cr of net profit in the Jun 26 quarter, −60.8% year on year. Full-year Mar 26 profit was ₹2,137 Cr. The operating margin ran 8.0% in the latest quarter. — as of 31 July 2026.
What is ACC Ltd's market cap?
ACC Ltd's market capitalisation is ₹25,490 Cr at a share price of ₹1,357. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is ACC Ltd's P/E ratio?
ACC Ltd trades at a P/E of 13.4×, at the 9th percentile of its own 10-year range, against a long-run median of 23.4×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does ACC Ltd pay a dividend?
Yes — ACC Ltd's dividend payout was 7% of profit in FY26, and it recorded a payout in each of its last 13 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 31 July 2026.
Is ACC Ltd overvalued?
On its own history, ACC Ltd looks cheap against its own history: its P/E of 13.4× has been cheaper only 9% of the time in 10 years (long-run median 23.4×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is ACC Ltd growing?
Not right now — ACC Ltd's latest numbers are shrinking: latest-quarter revenue −4.6% year on year, profit −60.8%, and the margin −5.0 pp at 8.0%. The 11-year compound rates are 7.5% (revenue) and 12.5% (profit). The earnings engine currently reads: deteriorating — as of 31 July 2026.
How is ACC Ltd performing?
ACC Ltd is in a downtrend, 93 weeks in. Its latest quarter's revenue fell 4.6% and profit fell 60.8% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 42 weeks. This describes what the data did, not a rating. — as of 31 July 2026.
What stage is ACC Ltd in?
Deteriorating — profit and EPS growth are shrinking (profit growth −21.1% latest against +377.5% at its 12-quarter best), ROCE slipping at 10.9%. The read comes from the last 12 quarters of growth (revenue growth +11.5% latest, profit growth −21.1% latest, eps growth −21.1% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is ACC Ltd in an uptrend?
No — the price is in a downtrend (week 93 of stage 4), trading −11.5% versus its 200-day average and at 8% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is ACC Ltd beating the market?
Not lately — on a trailing-13-week view ACC Ltd is currently behind the NIFTY 500 (42 weeks and counting; last ahead the week of 2025-10-31), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.4 years the stock moved +11% against the NIFTY 500's +276% — behind the index over the full window. — as of 31 July 2026.
Will ACC Ltd's share price go up?
This page publishes no price forecast for ACC Ltd. What it measures instead: the share price is ₹1,357, the price is in a downtrend 93 weeks in. Its P/E of 13.4× sits at the 9th percentile of its own 10-year range. Direction is not something this site claims to know. — as of 31 July 2026.
Who owns ACC Ltd?
Promoters hold 56.7% of ACC Ltd, foreign institutions 5.8%, domestic institutions 21.1% and the public 16.2% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 3.7 points over 8 quarters. — as of 31 July 2026.
Does ACC Ltd have too much debt?
No — ACC Ltd's debt-to-equity is 0.02, and operating profit covers the interest bill 26×. Mar 26 borrowings were ₹429 Cr against equity of ₹20,551 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is ACC Ltd's capex?
ACC Ltd spent ₹7,291 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In Mar 26 alone that was ₹1,711 Cr, with ₹2,227 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 31 July 2026.
What is ACC Ltd's cash flow?
ACC Ltd generated ₹−1,364 Cr of operating cash flow in Mar 26 and ₹−3,075 Cr of free cash flow after ₹1,711 Cr of capital spending. Reported profit that year was ₹2,137 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is ACC Ltd's profit real cash?
Not fully — over the last 3 fiscal years, 49% of ACC Ltd's reported profit arrived as operating cash. In Mar 26, operating cash was ₹−1,364 Cr against reported profit of ₹2,137 Cr. The cash then goes mostly into the working-capital cycle. Cash-flow resolution is annual — as of 31 July 2026.
Where is ACC Ltd in its business cycle?
ACC Ltd's Mar 26 operating margin was 11.0%, against a 13-year band of 9.0%–19.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 8.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the ACC Ltd story?
The sharpest disagreement: the P/E sits at the 9th percentile of its own range, but the engine is deteriorating — cheap for a reason until the quarters turn. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is ACC Ltd a stock worth studying right now?
This is not investment advice. The machine read: ACC Ltd is cheap for a reason. The P/E sits at the 9th percentile of its own range, and the quarters are still getting worse. The sharpest open question: whether the quarters turn before the discount closes. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.